



## Short profile Persimio Ltd.

CHARITÉ/BIH-PARTNER WANTED!  
More information [here](#)

Medical field	Oncology, Orthopedic Surgery
Product	Simfini TUMOR, Medical Device, Diagnostics
Growth stage	Positioning for Scale, CE-marked
Team	Dr. Yaniv Dolev (CEO), Prof. Zohar Yosibash (Founder & CTO), Kent Myers (Founder & Principal Software Engineer), Dr. Nir Trabelsi (Founder & Chief Engineering Analyst)

### Description of product:

Software that determines the risk for fracture due to metastatic bone disease in the femur by analyzing CT scans.

Sternheim, A et al. "When and where do patients with bone metastases actually break their femurs?." The bone & joint journal vol. 102-B,5 (2020): 638-645. doi:10.1302/0301-620X.102B5.BJJ-2019-1328.R2

### Project goal:

- (1) The data obtained in the clinical trial will be submitted to the FDA
- (2) Scientific papers
- (3) The physicians will participate in the scientific literature and will serve as KoL in scientific medical conferences
- (4) Co-ownership of future IPs.

### Project type:

The product is a software product that resides on the hospital's computers or a computer to be brought to the hospital by the company that uses CT scans already available in the PACS system of the hospital. The software is already installed in Sourasky Medical Center in Tel-Aviv without any inconvenience.

Estimated Project Duration: 12 months that can be extended according to needs.



Eligible by the IIA



[yaniv.dolev@gpersimio.com](mailto:yaniv.dolev@gpersimio.com)



Dr. Dolev: +972-52-891-1618



[www.persimio.com](http://www.persimio.com)

